Interestingly, as early as 2014, a clinical study of oral AG-221 was carried out in patients with advanced solid tumors, including gliomas with IDH2 mutation and angioimmunoblastic T-cell lymphoma. Here, IDH2 is linked to angioimmunoblastic T-cell lymphoma.